home / stock / nvo / nvo news


NVO News and Press, Novo Nordisk A/S From 06/25/24

Stock Information

Company Name: Novo Nordisk A/S
Stock Symbol: NVO
Market: NYSE
Website: novonordisk.com

Menu

NVO NVO Quote NVO Short NVO News NVO Articles NVO Message Board
Get NVO Alerts

News, Short Squeeze, Breakout and More Instantly...

NVO - Pfizer's Working on the Next Wegovy, but Can It Beat Novo Nordisk?

2024-06-25 09:45:00 ET It's obvious why Pfizer (NYSE: PFE) is eager to produce a medicine like Wegovy, Novo Nordisk 's (NYSE: NVO) smash-hit obesity therapy that's essentially a slightly different version of its type 2 diabetes drug called Ozempic. With such a gargantuan mar...

NVO - Wall Street Breakfast Podcast: Boeing Shifts To Stock Deal To Acquire Spirit Aerosystems

2024-06-25 06:53:51 ET Summary Boeing offers to buy Spirit Aero for $35 per share mainly in stock. Novo Nordisk to invest $4.1B in N.C. facility for obesity drugs. Oracle warns TikTok ban in U.S. could impact earnings. Listen below or on the go on Apple Podcasts ...

NVO - Novo Nordisk's Wegovy gets the green light in China

2024-06-25 05:10:40 ET Novo Nordisk ( NVO ) is up 2.1 % in premarket trade after the company's Wegovy weight loss treatment was approved in the world's second-largest economy.... Read the full article on Seeking Alpha For further details see: Novo Nordisk's Wegov...

NVO - Novo Nordisk to spend $4.1B to build new plant for obesity drugs in N.C.

2024-06-24 14:51:58 ET More on Novo Nordisk Novo Nordisk: Leading The Fight Against Diabetes And Obesity Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study Lilly, Novo Nordisk to d...

NVO - Zealand Pharma: Weight Loss Drug Petrelintide Is Not A 'Me Too' Advancement

2024-06-24 13:05:06 ET Summary Zealand Pharma A/S petrelintide showed promising results in a phase 1b study, with patients achieving up to 8.6% weight loss over 16 weeks at the highest dose. The global obesity market could reach $77 billion in 2030. Survodutide, dapiglutide, a...

NVO - Altimmune jumps 13% on phase 2 pemvidutide results for obesity

2024-06-24 09:21:19 ET More on Altimmune Altimmune: Going All-In On Pemvidutide Altimmune: A Potential Minor Player In The Massive GLP-1 Space Altimmune's Pemvidutide Is Not To Be Dismissed Altimmune Q1 2024 Earnings Preview Altimmune falls after Q4 r...

NVO - Lilly, Novo Nordisk to dominate weight loss therapy market: SA Investing Summit

2024-06-23 14:00:00 ET More on Eli Lilly, Novo Nordisk Eli Lilly: The Party Is Probably Nearing The End Novo Nordisk: Leading The Fight Against Diabetes And Obesity SA Asks: Who will launch the next big weight-loss drug? SA Asks: Is Eli Lilly or Novo No...

NVO - GLP-1 drugs linked to reduced dementia risk: study

2024-06-22 11:00:00 ET More on Eli Lilly, Novo Nordisk, etc. Eli Lilly: The Party Is Probably Nearing The End Novo Nordisk: Leading The Fight Against Diabetes And Obesity Eli Lilly And Alzheimer's Disease: The Paucity Of Progress ResMed, Philips under pressur...

NVO - Catalent gains after Sarepta's Elevidys gets label expansion

2024-06-21 10:03:58 ET More on Catalent Catalent shareholders approve acquisition by Novo Holdings Catalent, Novo Nordisk receive FTC request for more information Seeking Alpha’s Quant Rating on Catalent Historical earnings data for Catalent Fi...

NVO - Hims & Hers defended at BofA as Lilly fights compounded GLP-1s

2024-06-21 09:44:16 ET More on Hims & Hers Health Hims & Hers: The Undervalued Gem Poised For Growth Hims & Hers: Compounded Semaglutide Boost Unlikely To Last - Moderate Risks Ahead Hims & Hers: Ready For Takeoff Hims & Hers cut to Neutra...

Previous 10 Next 10